1
Clinical Trials associated with JPB-898A Randomized, Double-blind, Parallel-group Study to Compare Pharmacokinetics, Efficacy, Safety, and Immunogenicity of JPB898 (proposed Nivolumab Biosimilar) and US-licensed and EU-authorized Opdivo® in Combination with Yervoy® in Participants with Untreated Advanced (unresectable/metastatic) Melanoma
The purpose of the study is to demonstrate similar PK and efficacy and to show comparable safety and immunogenicity between JPB898, Opdivo-EU, and Opdivo-US, all administered in combination with Yervoy-EU (induction phase only), in participants with advanced (unresectable Stage III or metastatic Stage IV) melanoma.
100 Clinical Results associated with JPB-898
100 Translational Medicine associated with JPB-898
100 Patents (Medical) associated with JPB-898
100 Deals associated with JPB-898